In:
Oncology, S. Karger AG, Vol. 72, No. 5-6 ( 2007), p. 302-307
Abstract:
〈 i 〉 Background: 〈 /i 〉 Recurrent malignant glioma has a dismal prognosis, and therapeutic options are scarce. After previous potentially encouraging reports on liposomal pegylated doxorubicin (PEG-DOX) in this setting, PEG-DOX was applied to patients with recurrent malignant glioma in an institutional series. 〈 i 〉 Methods: 〈 /i 〉 In a retrospective analysis, 49 patients with recurrent high-grade glioma (WHO III, n = 18; WHO IV, n = 31) were treated with PEG-DOX (days 1 and 14/28, 20 mg/m 〈 sup 〉 2 〈 /sup 〉 , n = 26) alone or in combination with temozolomide (days 1–5/28, 200 mg/m 〈 sup 〉 2 〈 /sup 〉 , n = 23). The response rate, progression-free survival and overall survival were evaluated. 〈 i 〉 Results: 〈 /i 〉 The rate of progression-free patients at 6 months after initiation of therapy was 27% (WHO III, 33%; WHO IV, 23%). The median overall survival (mOS) after initiation of PEG-DOX (monotherapy and combination therapy) was 8 months (WHO III, 16 months; WHO IV, 7 months). The mOS after initiation of PEG-DOX monotherapy was 8 months, and after initiation of combination therapy, 10 months. Both regimens were well tolerated, with the main side effect being hematologic toxicity (grade 1–2, 8%; grade 3–4, 18%). 〈 i 〉 Conclusion: 〈 /i 〉 These data demonstrate the safety and moderate efficacy of PEG-DOX ± temozolomide therapy in recurrent malignant glioma. The potential of this nonalkylating chemotherapy should be further explored.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2007
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6
Permalink